Ghana's First Precision Medicine Company Completes German Development Grant Programme, Delivering Measurable Impact Across Patient Access, Diagnostic Innovation, and Clean Energy
Africa's Only Laboratory to Hold Triple ISO Accreditation from A2LA (the American Association for Laboratory Accreditation)
ISO 15189:2022 (Cert. No. 6990.01) | ISO 20387:2018 (Cert. No. 6990.02) | ISO/IEC 17043:2023 (Cert. No. 6990.03)
Revna Biosciences, Ghana's first precision medicine company, is contributing to transforming the landscape of healthcare in Ghana by offering advanced molecular tests for oncology, infectious diseases, etc. locally. Tests that were previously only available overseas due to technological constraints, often taking weeks to return results, are now accessible within the country and completed in a matter of days. This strategic move has reduced turnaround time for test results by up to 90%, a shift that translates directly into earlier diagnosis, timelier treatment decisions, and improved patient outcomes, while also making advanced diagnostics more affordable and accessible.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714775354/en/ Dr. Derrick E. Apkalu Co-Founder & CEO, Revna Biosciences
